Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C
https://doi.org/10.22625/2072-6732-2023-15-2-132-138
Abstract
Aim – to evaluate the effect of direct antiviral drugs (sofosbuvir and velpatasvir) on the formation of the metabolic syndrome in patients with chronic hepatitis C with a high risk of its development 2 years after treatment.
Materials and methods. 112 patients with HCV (n=112) were examined, in whom the risk of developing the metabolic syndrome was determined using a specially developed method. In 58 patients, a high risk of developing metabolic syndrome was identified. This cohort of patients was divided into two groups: group 1 (n=26) who took sofosbuvir and velpatasvir and group 2 (n=32) who did not take AVT. Patients were periodically examined and observed for 2 years. At the final stage of observation, a comparative analysis of laboratory and instrumental data was carried out in patients in two comparison groups.
Results. At the start of AVT, HCV patients with a high risk of developing metabolic syndrome were found to be over-weight, moderately pronounced stage of liver fibrosis (F2 according to METAVIR), high viral load, increased transaminases, total low-density lipoprotein cholesterol, atherogenic coefficient, insulin, glucose. Two years after the etiotropic therapy in HCV patients with a high risk of developing the metabolic syndrome, normalization of blood lipid metabolism, glucose, insulin levels and a decrease in the concentration of total thyroxine were registered.
Conclusion. Etiotropic therapy with direct antiviral drugs in patients with chronic hepatitis C reduces the relative risk of developing the metabolic syndrome by 6,3 times.
About the Authors
A. F. Novikova
Samara State Medical University
Russian Federation
Russian Federation
Samara
D. A. Kokorev
Samara State Medical University
Russian Federation
Russian Federation
Samara
D. Yu. Konstantinov
Samara State Medical University
Russian Federation
Russian Federation
Samara
L. L. Popova
Samara State Medical University
Russian Federation
Russian Federation
Samara
References
1. Tkachenko, L.I. Rol’ ozhireniya v razvitii metabolicheskih narushenij, progressirovanii fibroza pecheni i iskhodov protivovirusnoj terapii u bol’nyh hronicheskim gepatitom C / L. I. Tkachenko, V. V. Maleev, T. N. Cvetkovskaya // Epidemiologiya i infekcionnye bolezni. Aktual’nye voprosy. – 2016. – № 1. – S. 22-31.
2. Meissner, E.G. Rapid changes in peripheral lymphocyte concentrations during the treatment of chronic hepatitis C infection / E. G. Meissner, А. Kohli, J. Higgins [et al.] // Hepatology Communications. – 2017. - № 1. – P. 586-594.
3. Burchill, M.A. Rapid change in congenital immune dysregulation in the blood of patients and liver of humanized mice with HCV after therapy with DAA / M. A. Burchill, J. A. Roby, N. Crochet [et al.] // PLoS One. – 2017. – Vol. 17. – P. 186-213.
4. ZHdanov, K.V. Eliminaciya HCV-infekcii: istoriya s prodolzheniem / K.V. ZHdanov, K.V. Kozlov, V.S. Sukachev [i dr.] // ZHurnal infektologii. – 2018. – T.10, № 4. – S. 6 - 13
5. Patlusov, E. P. Rol’ metabolicheskih i immunologicheskih narushenij v progressirovanii hronicheskogo gepatita C / E. P. Patlusov, ZH.B. Ponezheva, I.V. Mannanova // Russkij medicinskij zhurnal. – 2019. – T. 27, № 10. – S. 7-11.
6. Pereira, G.L. Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients / G. L. Pereira, A. M. Tarragô, W. L. Lima Neves [et al.] // Mediators of Inflammation. – 2019. – № 4 (Nov). – P. 473-482.
7. Vita, S. Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection / S. Vita, P. Zuccalà, S. Savinelli [et al.] // Journal of Immunology Research. – 2020. – Mar 16. – P. 278.
8. Pandya, P.K. Metabolic syndrome in veterans with chronic HCV infection correlates with NAFLD activity score / P. K. Pandya, P. Shah, P. Callahan [et al.] // Gastroеnterology. – 2006. – Vol. 130. – P. 284.
9. Grigorescu, M. Metabolic syndrome, insulin resistance, and adiponectin level in patients with chroic hepatitis C / M. Grigorescu, C. Radu, D. Crişan [et al.] //Journal of Gastrointestinal and Liver Diseases. – 2008. – №17. – Р. 147-154.
10. Carvalho, R.F. Adiponectin levels and insulin resistance among patients with chronic hepatitis C / R. F. Carvalho, A. M. Atta, I. S. Oliveira [et al.] // Acta Tropica. – 2018. – Vol. 178. – P. 258-263.
11. Mauss, S. Effect of antiviral therapy for HCV on lipid levels / S. Mauss, F. Berger, M. H. Wehmeyer [et al.] // Antiviral Therapy. – 2017. – Vol. 21. – P. 81-88.
12. Konstantinov, D. YU. Vliyanie protivovirusnoj terapii i genotipa virusa na stepen’ vyrazhennosti zhirovogo gepatoza u bol’nyh hronicheskim gepatitom S s lipidnym distress-sindromom / D. YU. Konstantinov // Aspirantskij vestnik Povolzh’ya. – 2016. – №1-2. – S. 82-86.
13. Novikova, A.F. Vozmozhnosti prognozirovaniya razvitiya metabolicheskogo sindroma u pacientov hronicheskim virusnym gepatitom S pri otsutstvii protivovirusnoj terapii / A. F. Novikova, D. YU. Konstantinov, G. V. Nedugov [i dr.] // Prakticheskaya medicina. – 2019. – T. 17, № 8. – S. 40-43.
14. Popova, L.L. Kliniko-patogeneticheskoe obosnovanie strategii i taktiki immunoterapii pri hronicheskom virusnoj gepatite S: dis. d-ra med. nauk: 14.00.10, 14.00.36: zashchishchena 19.10.2009 / Popova Larisa Leonidovna. – Samara, 2009. – 337 s.
15. Chen, L. Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients / L. Chen, W. Liu, S. Lai [et al.] // European Journal of Gastroenterology & Hepatology. – 2013. – Vol. 25 (Aug). – P. 935-941.
16. González-Reimers, E. Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis / E. González-Reimers, J. López-Prieto, G. Quintero-Platt [et al.] // World Journal of Hepatology. – 2016. – Vol. 8 (Jan). – P. 74-82.
17. Naseem, S. Interleukin-6 Rescues Lymphocyte from Apoptosis and Exhaustion Induced by Chronic Hepatitis C Virus Infection/ S. Naseem, S. Manzoor, A. Javed, S. Abbas // Viral Immunology. – 2018. – Vol. 31 (Nov). – P. 624-631.
18. Durazzo, M. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis / M. Durazzo, P. Belci, G. Niro [et al.] // Journal of Endocrinological Investigation. – 2013. – Vol. 36 (Sep). – P. 600-605.
19. Bastard, J.-P. Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis / J.-P. Bastard, S. Fellahi, É. Audureau [et al.] // European Cytokine Network. – 2018. – Vol. 29 (Sep). – P. 112-120.
20. Patent № 2684524 Rossijskaya Federaciya, MPK G01N 33/48 (2006.01), G01N 33/48 (2018.08). Sposob prognozirovaniya razvitiya metabolicheskogo sindroma u pacientov s hronicheskim virusnym gepatitom S [Tekst] / Novikova A. F., Konstantinov D. YU., Nedugov G. V., Popova L. L., Suzdal’cev A. A., Konstantinova E. A. ; zayavitel’ i patentoobladatel’ Federal’noe gosudarstvennoe byudzhetnoe obrazovatel’noe uchrezhdenie vysshego obrazovaniya «Samarskij gosudarstvennyj medicinskij universitet» Ministerstva zdravoohraneniya Rossijskoj Federacii. – №20181187; zayavl. 21.05.2018; opubl. 09.04.2019, Byul. № 10 –8s.: il.
21. Svidetel’stvo o gosudarstvennoj registracii programmy dlya EVM №2020660229 Rossijskaya Federaciya. Programma prognozirovaniya razvitiya metabolicheskogo sindroma pri hronicheskom virusnom gepatite S [Tekst] / A. F. Novikova, D. YU. Konstantinov, G. V. Nedugov, L. L. Popova, E. A. Konstantinova; zayavitel’ i pravoobladatel’ A. F. Novikova, D. YU. Konstantinov, G. V. Nedugov, L. L. Popova, E. A. Konstantinova – № 2020619389 ; zayavl. 18.08.2020 ; opubl. 31.08.2020. – 1 s.
22. Patlusov, E.P. Osobennosti narusheniya lipidnogo i uglevodnogo obmena u bol’nyh hronicheskim gepatitom C v zavisimosti ot genotipa virusa / E. P. Patlusov, I. E. Valamina, P. L. Kuznecov [i dr.] // Medicinskij vestnik Bashkortostana. – 2019. – T. 14, № 5. – S. 23-30.
23. Kalra, S. Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management / S. Kalra, S. Aggarwal, D. Khandelwal // Diabetes Therapy. – 2019. – Vol.10. – P. 2035-2044.
24. Zhuo, L.Y. Study on thyroid hormone levels and influence factors in drug users in a drug rehabilitation center in Jiangsu province / L. Y. Zhuo, P. Huang, H. Z. Fan [et al.] // Zhonghua Liu Xing Bing Xue Za Zhi. – 2019. – Vol. 40. – P. 1134-1138.
25. Tkachenko, L.I. Kliniko-patogeneticheskaya rol’ narushenij uglevodnogo i lipidnogo obmena u bol’nyh hronicheskimi virusnymi gepatitami: prognozirovanie i optimizaciya terapii: dis. … d-ra med. nauk : 14.01.09: zashchishchena 19.05.2017 / Tkachenko Larisa Ivanovna. – Stavropol’, 2016. – 366 s. : il.
Review
For citations:
Novikova A.F., Kokorev D.A., Konstantinov D.Yu., Popova L.L. Effects of antiviral therapy on reducing the risk of metabolic syndrome in patients with chronic hepatitis C. Journal Infectology. 2023;15(2):132-138. (In Russ.) https://doi.org/10.22625/2072-6732-2023-15-2-132-138
Views:
398
.png)
.png)
Email this article 